These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29533778)

  • 1. ORY-1001: Overcoming the Differentiation Block in AML.
    Bose P; Konopleva MY
    Cancer Cell; 2018 Mar; 33(3):342-343. PubMed ID: 29533778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
    Maes T; Mascaró C; Tirapu I; Estiarte A; Ciceri F; Lunardi S; Guibourt N; Perdones A; Lufino MMP; Somervaille TCP; Wiseman DH; Duy C; Melnick A; Willekens C; Ortega A; Martinell M; Valls N; Kurz G; Fyfe M; Castro-Palomino JC; Buesa C
    Cancer Cell; 2018 Mar; 33(3):495-511.e12. PubMed ID: 29502954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
    Salamero O; Montesinos P; Willekens C; Pérez-Simón JA; Pigneux A; Récher C; Popat R; Carpio C; Molinero C; Mascaró C; Vila J; Arévalo MI; Maes T; Buesa C; Bosch F; Somervaille TCP
    J Clin Oncol; 2020 Dec; 38(36):4260-4273. PubMed ID: 33052756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
    Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
    Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
    Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
    Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of histone demethylase lysine specific demethylase 1 in acute leukemia and its clinical significance].
    Lin XM; Zhong WT; Wang CL; Wang SQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1348-52. PubMed ID: 22169281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel lysine-specific histone demethylase 1 inhibitor in acute myeloid leukaemia transformed from essential thrombocythaemia.
    Hodges S; Cooney J
    Cancer Rep (Hoboken); 2022 Aug; 5(8):e1588. PubMed ID: 34786883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
    McGrath JP; Williamson KE; Balasubramanian S; Odate S; Arora S; Hatton C; Edwards TM; O'Brien T; Magnuson S; Stokoe D; Daniels DL; Bryant BM; Trojer P
    Cancer Res; 2016 Apr; 76(7):1975-88. PubMed ID: 26837761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
    Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
    Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
    Sugino N; Kawahara M; Tatsumi G; Kanai A; Matsui H; Yamamoto R; Nagai Y; Fujii S; Shimazu Y; Hishizawa M; Inaba T; Andoh A; Suzuki T; Takaori-Kondo A
    Leukemia; 2017 Nov; 31(11):2303-2314. PubMed ID: 28210006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
    Curtiss BM; VanCampen J; Macaraeg J; Kong GL; Taherinasab A; Tsuchiya M; Yashar WM; Tsang YH; Horton W; Coleman DJ; Estabrook J; Lusardi TA; Mills GB; Druker BJ; Maxson JE; Braun TP
    Leukemia; 2022 Jul; 36(7):1781-1793. PubMed ID: 35590033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1.
    Ge W; Liu Y; Chen T; Zhang X; Lv L; Jin C; Jiang Y; Shi L; Zhou Y
    Biomaterials; 2014 Jul; 35(23):6015-25. PubMed ID: 24794925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.
    Fang J; Ying H; Mao T; Fang Y; Lu Y; Wang H; Zang I; Wang Z; Lin Y; Zhao M; Luo X; Wang Z; Zhang Y; Zhang C; Xiao W; Wang Y; Tan W; Chen Z; Lu C; Atadja P; Li E; Zhao K; Liu J; Gu J
    Oncotarget; 2017 Oct; 8(49):85085-85101. PubMed ID: 29156705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
    Boila LD; Chatterjee SS; Banerjee D; Sengupta A
    Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
    Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
    Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.